Related by context. All words. (Click for frequent words.) 70 androgen deprivation 68 hormonal therapy 66 EBRT 65 GnRH agonists 65 localized prostate cancer 64 androgen suppression therapy 64 preoperative chemotherapy 63 bisphosphonate therapy 63 chemoradiotherapy 63 androgen suppression 62 orchiectomy 62 bisphosphonates 62 tamoxifen 62 adjuvant therapy 62 chemoradiation 61 estrogen therapy 61 prostate cancer CRPC 61 cystectomy 61 antidepressant therapy 61 nonmetastatic prostate cancer 61 external beam radiotherapy 61 AVODART 61 Androgen deprivation therapy 61 hormone therapy 61 radical prostatectomy 60 metastatic prostate cancer 60 tamoxifen therapy 60 oophorectomy 60 intravenous bisphosphonates 60 testosterone supplementation 60 GnRH agonist 60 hormonal therapies 60 ALND 60 zoledronic acid 60 oral bisphosphonates 60 LHRH agonists 60 androgen deficiency 60 mycophenolate mofetil 60 recurrent prostate cancer 60 clinically localized prostate 60 anastrozole 59 adjuvant radiotherapy 59 corticosteroid therapy 59 adjuvant radiation 59 osteoporotic 59 neoadjuvant chemotherapy 59 endometrial hyperplasia 59 statins 59 subclinical hypothyroidism 59 warfarin therapy 59 Adjuvant chemotherapy 59 spine fractures 59 bone metastases 59 renal dysfunction 59 adjuvant chemotherapy 59 postoperative chemotherapy 59 Tamoxifen 59 clodronate 59 nonmelanoma skin cancers 59 bisphosphonate 59 cisplatin chemotherapy 58 APTIVUS r 58 serum PSA 58 aromatase inhibitor therapy 58 osteoporotic fracture 58 androgen ablation 58 sentinel node biopsy 58 menopausal hormone therapy 58 estrogen progestin therapy 58 metastatic disease 58 cabazitaxel 58 letrozole 58 vitamin D supplementation 58 docetaxel chemotherapy 58 neoadjuvant therapy 58 bicalutamide 58 glucocorticoid therapy 58 biochemical recurrence 58 tamsulosin 58 dutasteride 58 teriparatide 58 urinary symptoms 58 beta blocker therapy 57 calcitriol 57 axillary dissection 57 neoadjuvant 57 anthracyclines 57 exemestane 57 radiation therapy 57 vandetanib 57 radical nephrectomy 57 beam radiotherapy 57 metastatic RCC 57 flutamide 57 atypical antipsychotic drugs 57 metastatic castration resistant 57 advanced adenomas 57 temsirolimus 57 FOLFOX4 57 metastatic renal cell carcinoma 57 lipid lowering therapy 57 statin therapy 57 TACE 57 elevated CRP 57 aspirin therapy 57 idarubicin 57 DMARDs 57 cytotoxic chemotherapy 57 thromboembolic events 57 mitoxantrone 57 tibolone 57 loop diuretics 57 endometrial cancers 57 adenoma 57 NSAIDs 57 subtrochanteric 57 cardiovascular morbidity 57 postmenopausal hormone therapy 57 transurethral resection 57 Doxil ® 57 standard chemotherapy regimen 57 peginterferon 57 curative resection 57 parathyroidectomy 57 hypercalcemia 57 cranial irradiation 57 risedronate 57 LHRH agonist 57 vertebral fracture 57 adalimumab 57 ARIMIDEX 57 hormone therapy estrogen 56 extrapyramidal symptoms EPS 56 TURP 56 chemotherapeutic regimens 56 HER2 positive breast cancer 56 goserelin 56 osteoporotic fractures 56 elevated serum creatinine 56 immunosuppressive agents 56 glucocorticoids 56 recurrent VTE 56 loop diuretic 56 NATRECOR ® 56 endometrial carcinoma 56 hip BMD 56 prostatectomy 56 myelosuppression 56 estrogen deficiency 56 placebo dexamethasone 56 trastuzumab 56 lymph node removal 56 cyclophosphamide 56 CIN3 56 hyperplasia BPH 56 alendronate 56 prostate TURP 56 anticoagulation therapy 56 fluorouracil 56 grade gliomas 56 prostate specific antigen 56 aldosterone antagonist 56 dacarbazine 56 WBRT 56 antipsychotic medications 56 serum calcium levels 56 gemcitabine Gemzar 56 leucovorin 56 bone metastasis 56 Metastatic Prostate Cancer 56 IV bisphosphonates 56 antidepressant medications 56 unresectable tumors 56 progestins 56 antiplatelet therapy 56 tumor recurrence 56 imatinib 56 L dopa 56 contralateral breast cancer 56 cytoreductive surgery 56 perimenopausal women 56 tocilizumab 56 cervical lesions 56 pegylated liposomal doxorubicin 56 FOLFIRI 56 hormone deprivation 56 cardiotoxicity 56 abiraterone 56 5FU 56 adenoma recurrence 56 DMARD 55 Cisplatin 55 antithrombotic therapy 55 5-FU/LV 55 antiarrhythmic drugs 55 typical antipsychotics 55 FASLODEX 55 sorafenib Nexavar 55 hormone receptor positive 55 pCR 55 aminotransferases 55 spironolactone 55 breast cancer recurrence 55 distant metastases 55 PREZISTA r 55 locoregional 55 antihypertensive therapy 55 antiandrogens 55 systemic corticosteroid 55 paclitaxel eluting stents 55 perioperative morbidity 55 androgen therapy 55 transaminase levels 55 temozolomide 55 postoperative mortality 55 hydroxychloroquine 55 axillary lymph node dissection 55 serum testosterone 55 PSADT 55 BYSTOLIC 55 interferon alfa 55 lymph node dissection 55 docetaxel 55 aromatase inhibitor 55 locoregional recurrence 55 LUTS 55 DMARD therapy 55 aromatase inhibitors 55 tricyclic antidepressants 55 chemotherapy regimens 55 cisplatin 55 polyp recurrence 55 nonvertebral fractures 55 abatacept 55 undergoing radical prostatectomy 55 dopamine agonists 55 prostate biopsy 55 bevacizumab Avastin 55 contralateral breast 55 paroxysmal AF 55 androgen independent 55 EGFR inhibitors 55 celecoxib 55 Benign prostatic hyperplasia BPH 55 recurrent glioblastoma multiforme 55 venous thromboembolism 55 sentinel lymph node biopsy 55 pneumonectomy 55 perioperative mortality 55 adenomas 55 adenomatous polyps 55 carotid stenosis 55 luteinizing hormone releasing 55 PCa 55 debulking surgery 55 medically inoperable 55 Bosentan 55 endometrial cancer 55 vinorelbine 55 DAPT 55 candesartan 55 valproate 55 serum phosphate 55 eribulin 55 metastatic kidney 55 comorbidities 55 rituximab 55 octreotide LAR 55 advanced adenoma 55 infliximab Remicade 55 B7 H3 55 premenopausal 55 epithelial ovarian 55 methotrexate 55 TZDs 55 prostate cancer HRPC 55 HER2 positive metastatic breast 55 bilateral oophorectomy 55 metformin 55 Torisel 55 prostate cancer CaP 55 mRCC 55 HMG CoA reductase inhibitors 55 invasive coronary angiography 55 neoadjuvant radiation 55 isotretinoin 55 amenorrhoea 54 Kaplan Meier analysis 54 Hydroxyurea 54 epithelial tumors 54 hormone refractory prostate cancer 54 chemoembolization 54 stage IIIB 54 statin medications 54 postmenopausal women 54 ibandronate 54 brain metastases 54 antihypertensive medications 54 entecavir 54 unfractionated heparin 54 colorectal liver metastases 54 specific antigen PSA 54 hematologic toxicity 54 strontium ranelate 54 thrombolytic therapy 54 nonoperative treatment 54 anti androgen 54 dasatinib 54 ALA PDT 54 alteplase 54 cilostazol 54 PREMPRO 54 NATRECOR R 54 mammographic density 54 liver biopsies 54 neuroleptics 54 treat benign prostatic 54 H. pylori eradication 54 radioiodine therapy 54 post thrombotic syndrome 54 antiplatelet medication 54 β blockers 54 alpha blocker 54 estrogen receptor negative 54 TNF antagonist 54 colectomy 54 adefovir 54 prostate adenocarcinoma 54 Venous thromboembolism 54 azacitidine 54 venous thromboembolic events 54 oral antidiabetic medication 54 castration resistant prostate cancer 54 imatinib therapy 54 EXJADE 54 SERMs 54 raloxifene Evista 54 gemcitabine chemotherapy 54 testosterone deficiency 54 upper gastrointestinal bleeding 54 levodopa 54 prostate specific 54 EDSS scores 54 radical cystectomy 54 anthracycline therapy 54 tolvaptan 54 leukemia AML 54 non squamous NSCLC 54 femoral shaft fractures 54 Tavocept 54 decitabine 54 asymptomatic carotid stenosis 54 radical prostatectomy RP 54 vertebral fractures 54 citalopram Celexa 54 MGd 54 generalized seizures 54 etanercept 54 allopurinol 54 underwent prostatectomy 54 adjuvant hormonal therapy 54 paricalcitol 54 fallopian tube carcinoma 54 doxorubicin HCl liposome injection 54 fluoxetine Prozac 54 Gliadel Wafer 54 vasomotor symptoms 54 calcium supplementation 54 nonfatal MI 54 gout flares 54 thromboprophylaxis 54 neurologic progression 54 carotid endarterectomy 54 anticonvulsant medications 54 pioglitazone 54 estrogen receptor positive 54 HAART 54 amenorrhea 54 superficial bladder cancer 54 varicoceles 54 antigen PSA 54 cytoreduction 54 perioperative complications 54 SHPT 54 HNSCC 54 atypical hyperplasia 54 fulvestrant 54 catheter angiography 54 prolactin levels 54 NRTIs 54 nonoperative 54 postmenopausal hormone 54 EFFEXOR XR 54 immunosuppressive therapies 54 intravesical therapy 54 postoperative AF 54 ABVD 54 carotid intima media 54 Mitoxantrone 54 poorer prognosis 54 androgen 54 CMV disease 54 adrenal suppression 54 chronic periodontitis 54 prednisone prednisolone 54 atypical ductal hyperplasia 54 HRPC 54 chemotherapies 54 raloxifene 54 HER2 negative 54 pertuzumab 54 weekly subcutaneous injections 54 Trastuzumab 54 azathioprine 54 differentiated thyroid 54 reperfusion therapy 54 HBeAg negative 54 cholesterol lowering medication 54 bosentan 54 FOLFOX6 53 Hormone therapy 53 colorectal neoplasms 53 renal impairment 53 thiazolidinedione 53 pyridostigmine 53 fluvastatin 53 cardiac toxicity 53 folate intake 53 colorectal cancer liver metastases 53 thiazide diuretic 53 secondary hypogonadism 53 EVISTA 53 left ventricular dysfunction 53 atypical fractures 53 nonmelanoma skin cancer 53 biochemical relapse 53 NSAID 53 renal function 53 relapsed ovarian cancer 53 urinary retention 53 dose cytarabine 53 allogeneic stem cell 53 nephrotoxicity 53 radiochemotherapy 53 revascularization procedures 53 8mg/kg 53 PSA screening 53 juvenile idiopathic arthritis 53 rosuvastatin 53 Bevacizumab 53 thromboembolic 53 BRAF mutation 53 d4T 53 gemcitabine 53 cranial radiation 53 relapsed AML 53 alkylating agent 53 Hurthle cell 53 FUSILEV enhances 53 paroxetine Paxil 53 cetuximab 53 antioxidant supplementation 53 axillary node dissection 53 AZILECT 53 axillary lymph nodes 53 antiemetics 53 chemotherapy 53 intact parathyroid hormone 53 Teriparatide 53 erlotinib Tarceva 53 bevacizumab 53 rosuvastatin #mg 53 dexrazoxane 53 chronic prostatitis 53 atypical antipsychotic medications 53 nonhormonal 53 statin 53 antihypertensive drugs 53 prostate cancer PCa 53 antipsychotic drugs 53 leiomyomas 53 T2DM 53 TNF inhibitor 53 postmenopausal hormones 53 dual antiplatelet therapy 53 microvascular disease 53 interferon therapy 53 endometriosis ovarian cysts 53 Anastrozole 53 chlamydial infection 53 lymphadenectomy 53 pancreatic adenocarcinoma 53 BENICAR HCT 53 cytotoxic therapy 53 DMPA 53 operable breast cancer 53 Cremophor 53 immunosuppressive medications 53 taxane chemotherapy 53 FROVA 53 pregabalin 53 radiotherapy RT 53 COPAXONE ® 53 endarterectomy 53 squamous cell cancers 53 beta carotene supplements 53 invasive candidiasis 53 moderate renal impairment 53 infusional 5-FU/LV 53 enlarged prostates 53 Platinol ® cisplatin 53 achieved ACR# 53 Adriamycin 53 vincristine doxorubicin 53 lipid elevations 53 prognostic factors 53 cholinesterase inhibitors 53 ORENCIA 53 octreotide 53 serum testosterone levels 53 interferon ribavirin 53 corticosteroids 53 hypogonadal 53 severe neutropenia 53 phosphate binders 53 adriamycin 53 CaP 53 non metastatic osteosarcoma 53 naturally occurring estrogen 53 abiraterone acetate 53 trimethoprim sulfamethoxazole 53 serum prostate 53 postoperative atrial fibrillation 53 prostate cancer 53 TORISEL 53 bowel resection 53 folinic acid 53 colorectal adenoma 53 antiepileptic medications 53 lymph node involvement 53 acid suppressing 53 IV NSCLC 53 immunosuppression 53 PSA nadir 53 abnormal mammograms 53 radiofrequency ablation RFA 53 comorbid conditions 53 androgens 53 non aspirin NSAIDs 53 mCRC patients 53 progesterone receptor negative 53 Radiation therapy 53 chemotherapy regimen 53 lupus nephritis 53 postoperative radiotherapy 53 chemo radiotherapy 53 Exemestane 53 endocrine therapy 53 splenectomized patients 53 bortezomib 53 EGFRIs 53 F FDG PET 53 reinfarction 53 colon polyps 53 dose aspirin 53 variceal hemorrhage 53 MULTAQ 53 colorectal polyps 53 polycystic ovary syndrome PCOS 53 BARACLUDE 53 antipsychotics 53 CMV infection 53 ximelagatran 53 clozapine 52 bladder cancers 52 anticancer therapy 52 esophageal cancers 52 thromboembolism 52 LYSTEDA 52 mitochondrial toxicity 52 ovarian function 52 epirubicin 52 Rectal cancer 52 hyperkalemia 52 NSAID therapy 52 VIDAZA 52 KRAS mutations occur 52 extrapyramidal symptoms 52 antiandrogen 52 salpingo oophorectomy 52 prostate cancers 52 sunitinib 52 ALT flares 52 antiviral therapy 52 abnormal Pap test 52 oral anticoagulants 52 HER2 overexpression 52 anti arrhythmic drugs 52 menopausal symptom 52 varicocele 52 grade glioma 52 deep venous thromboses 52 triptans 52 neoplasia PIN 52 letrozole Femara 52 microalbuminuria 52 inhaled steroids 52 osteopenic 52 CLA supplementation 52 Estrogen deficiency 52 aldosterone antagonists 52 breast irradiation 52 premenopausal women 52 aripiprazole 52 folate supplementation 52 ductal breast cancer 52 platelet reactivity 52 immunosuppressive regimen 52 Zometa 52 corticosteroid 52 undergone hysterectomy 52 pre menopausal 52 danazol 52 opioids 52 disease progression 52 #.#ng/ml 52 Taxotere chemotherapy 52 symptomatic fibroids 52 opioid analgesia 52 opioid therapy 52 TTF Therapy 52 chemoradiation therapy 52 sulfasalazine 52 clomiphene 52 metformin sulfonylurea 52 Radical prostatectomy 52 FOLFIRI alone 52 Navelbine 52 acute gout flares 52 pamidronate 52 pre cancerous lesions 52 thrombolytic agents 52 dose colchicine 52 sipuleucel T 52 tissue plasminogen activator tPA 52 cytoreductive nephrectomy 52 hypogonadism 52 ATACAND 52 nifedipine 52 denosumab 52 basal cell cancers 52 vaginal atrophy 52 Thal Dex 52 metastatic hormone refractory 52 thrombotic events 52 bone resorption 52 methotrexate MTX 52 monotherapy 52 ARB telmisartan 52 hydroxyurea 52 Estrogens 52 dexamethasone Decadron 52 BEACOPP 52 estramustine 52 neoadjuvant treatment 52 bladder carcinoma 52 irbesartan 52 pT2 52 cirrhotic patients 52 sorafenib tablets 52 GP IIb IIIa inhibitors 52 postoperative morbidity 52 periprocedural MI 52 tricyclic antidepressant 52 proctitis 52 cyclophosphamide methotrexate 52 urothelial cancer 52 adjunctive ABILIFY 52 DOXIL 52 mapatumumab 52 incidentalomas 52 COPAXONE R 52 anakinra 52 thromboembolic disease 52 AGILECT R 52 primidone 52 Retreatment 52 pimozide 52 uterine cancers 52 oncologic outcomes 52 BRCA1 mutations 52 breast conserving 52 nonpharmacologic 52 angiotensin converting enzyme inhibitors 52 PSA velocity 52 Capecitabine 52 undergone radical prostatectomy 52 proliferative diabetic retinopathy 52 TEAEs 52 cervical carcinoma 52 chlorambucil 52 QTc interval 52 methotrexate monotherapy 52 COREG 52 anthracycline taxane 52 Corticosteroids 52 thiazide diuretics 52 alkylating agents 52 androgen depletion therapy 52 Estradiol 52 BMD measurements 52 peginterferon alfa 52 ovulatory cycles 52 epithelial ovarian cancer 52 colorectal carcinoma 52 gastric atrophy 52 carboplatin paclitaxel 52 febrile neutropenia 52 bezafibrate 52 FOLFOX 52 interferon alfa 2b 52 pathologic fractures 52 watchful waiting 52 doxazosin 52 estrogen 52 subclinical hyperthyroidism 52 mitoxantrone chemotherapy 52 multivariate Cox 52 Hormonal therapy 52 Response Evaluation Criteria 52 radioimmunotherapy 52 seminoma 52 HoLEP 52 rFVIIa 52 benign prostatic hyperplasia 52 esophagectomy 52 vaginal progesterone 52 invasive breast cancer 52 FOLFIRINOX 52 generation antipsychotics 52 mg kg dose 52 KETEK 52 sustained virological response 52 Avodart 52 metastatic GIST 52 bilateral orchiectomy 52 DFMO 52 clozapine Clozaril 52 invasive carcinoma 52 atazanavir 52 Decitabine 52 estrogen receptor ER 52 symptomatic BPH 52 surrogate endpoint 52 Recurrence Score 52 tumor resection 52 TNF blockers 52 estradiol 52 SSRI 52 TMP SMX 52 dacarbazine chemotherapy 52 LVEF 52 Cytoxan 52 pelvic lymphadenectomy 52 Gemcitabine 52 lenalidomide Revlimid R 52 uric acid lowering 52 abacavir lamivudine 52 MRgFUS 52 bevacizumab Avastin ® 52 coronary artery calcium 52 nephrotoxic drugs 52 sorafenib 52 renal tumors 52 mIU L 52 breast carcinoma 52 antiepileptic drugs 52 chemotherapeutic drugs 52 Sandostatin LAR 52 prophylactic mastectomy 52 lenalidomide dexamethasone 52 plus prednisone 52 glitazones 52 lumbar disk herniation 52 conventional angiography 52 fragility fractures 52 intravenous diuretics 52 DOXIL ® 52 LHRH analogues 52 metastatic lung cancer 52 antidiabetic medication 52 Barrett esophagus 52 pancreatic NET 52 relapsed MM 52 abnormal Pap smears 52 chemopreventive agent 52 vitamin D insufficiency 51 aminotransferase levels 51 CVD mortality 51 skeletal metastases 51 protease inhibitor PI 51 steroid prednisone 51 coronary angiography 51 nephron sparing surgery 51 CYPHER Stent 51 ACE Inhibitors 51 grade cervical intraepithelial 51 recurrent venous thromboembolism 51 sertraline 51 Adjuvant therapy 51 ziprasidone 51 estrogen progestin combination 51 lipid lowering therapies 51 lipid lowering agents 51 medullary thyroid cancer 51 noncardiac 51 benign prostatic hypertrophy 51 precancerous lesions 51 Monotherapy 51 preterm delivery 51 antiplatelet drugs 51 nonadherence 51 Paraplatin ® 51 shock wave lithotripsy 51 Zoledronic Acid 51 gallstone disease 51 recurrent NSCLC 51 NMIBC 51 Calcitonin 51 adenomatous 51 metastatic cancer 51 treat menopausal symptoms 51 adrenalectomy 51 deep venous thrombosis 51 prior nephrectomy 51 coronary arteriography 51 doxorubicin 51 invasive aspergillosis 51 HER2 positive tumors 51 transaminase elevations 51 Neoadjuvant 51 progestin 51 serum calcium 51 precancerous tumors 51 eplerenone 51 AA Amyloidosis 51 tiotropium bromide 51 low dose cytarabine 51 LMWH 51 N telopeptide 51 FIRMAGON 51 atherothrombotic events 51 intraperitoneal chemotherapy 51 lobular cancer 51 lung metastases 51 neoplasia 51 Peg IFN 51 renal cell carcinomas 51 standard chemotherapy regimens 51 osteoporotic vertebral compression fractures 51 lobular carcinoma 51 interferon ribavirin combination 51 zolmitriptan 51 proliferative retinopathy 51 LHRH 51 fluconazole 51 thiazolidinediones 51 stable angina 51 VAPRISOL 51 chemotherapy cisplatin 51 micrometastases 51 postoperative complication 51 CYT# potent vascular disrupting 51 dose dexamethasone 51 interferon alfa 2a 51 levodopa therapy 51 lapatinib Tykerb 51 CellCept 51 atypia 51 thyrotropin levels 51 Follicular Lymphoma 51 concomitant medications 51 serotonin reuptake inhibitors 51 nonvertebral fracture 51 Platinol 51 underwent radical prostatectomy 51 total abdominal hysterectomy 51 radiation therapy SBRT 51 ribavirin therapy 51 Degarelix 51 APTIVUS ritonavir 51 secondary hyperparathyroidism 51 Herceptin trastuzumab 51 histologically confirmed 51 MGUS 51 gastrointestinal stromal tumors GIST 51 metastatic gastric 51 mycophenolate mofetil MMF 51 antiangiogenic therapy 51 postmenopausal 51 virologic failure 51 osteosarcomas 51 resectable 51 iniparib 51 BRCA2 mutations 51 lipid abnormalities 51 efalizumab 51 carcinomas 51 TNF inhibitors 51 paclitaxel Taxol 51 hepatic resection 51 advanced metastatic prostate 51 Surgical resection 51 hypoparathyroidism 51 HBeAg positive patients 51 colorectal adenomas 51 prostate carcinoma 51 selective serotonin reuptake inhibitor 51 recurrent ovarian cancer 51 specific antigen 51 lumbar spine BMD 51 Heavy menstrual bleeding 51 Invasive Breast Cancer 51 OPCAB 51 genistein 51 HBV infection 51 renal insufficiency 51 symptomatic VTE 51 hepatic metastases 51 sustained virologic response 51 hormone LHRH agonist 51 squamous histology 51 ZOMETA 51 peginterferon alfa 2a Pegasys 51 pomalidomide 51 anticoagulants blood thinners 51 venlafaxine Effexor 51 postoperative complications 51 tyrosine kinase inhibitors 51 underwent brachytherapy 51 colorectal neoplasia 51 adalimumab Humira 51 nevirapine Viramune 51 nucleoside analogue 51 Metastatic 51 CsA 51 6 mercaptopurine 51 spontaneous preterm birth 51 anti leukemic 51 DEXA scan 51 standby tamoxifen 51 ICD implantation 51 tretinoin 51 SSRIs 51 lobular breast cancer 51 intramuscular injections 51 NOLVADEX 51 ACTOplus met 51 hyperphenylalaninemia HPA due 51 autoantibody positive 51 XGEVA 51 thromboembolisms 51 intravenous cyclophosphamide 51 calcium supplements 51 endoxifen 51 antibiotic prophylaxis 51 tamoxifen Nolvadex ® 51 thoracoscopic lobectomy 51 inhaled corticosteroids 51 CA4P 51 situ CIS 51 FDG PET 51 ritonavir boosted 51 overactive bladder symptoms 51 tirofiban 51 Protelos 51 haemorrhagic stroke 51 Tindamax R 51 cardiac dysfunction 51 vitamin K1 51 EUS FNA 51 lipid lowering drugs 51 fragility fracture 51 onset diabetes mellitus 51 basiliximab 51 systolic hypertension 51 selenium intake 51 Bisphosphonates 51 prostatic hyperplasia 51 Telintra 51 unresectable 51 VTEs 51 Prostatitis 51 5 Fluorouracil 51 benign breast 51 elevated LDH 51 prognostic variables 51 RLS symptoms 51 levothyroxine